Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05800600 · ClinicalTrials.gov registry record · Phase 2
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
A Phase 2 study of Anemia, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05800600: Recruiting Phase 2 study of Anemia, sponsored by Fox Chase Cancer Center.
NCT05800600 is a Phase 2 study of Anemia that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 34 participants, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05800600, a Phase 2 study of Anemia, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of undergoing surgical resection.
Primary Outcome
To evaluate the efficacy of iron infusions in improving chemotherapy-induced anemia by improving the hemoglobin of patients undergoing neoadjuvant chemotherapy. Mean change from baseline to highest Hgb value observed six weeks after last iron infusion, before day of surgery.
Conditions Studied
Interventions
- DRUG Venofer
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 2 |
What NCT05800600 shows while recruiting
NCT05800600 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 1 intervention - of which Venofer is the first listed.
NCT05800600 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05800600 about?
NCT05800600 is a clinical study titled "Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy". This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of undergoing surgical resection.
What is the current status of trial NCT05800600?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2023-03-15. Estimated completion is 2027-02-01.
What conditions does trial NCT05800600 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT05800600?
The interventions under investigation include: Venofer (DRUG).
Who is sponsoring clinical trial NCT05800600?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05800600 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05800600's enrollment target sits among peer trials
34 63rd of 72 higher than 10 of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Choline and Iron Deficiency
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI